Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 11:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Not applicable Interventional Results available

Preemptive Resuscitation for Eradication of Septic Shock

NCT01449721
Conditions
Sepsis, Severe Sepsis
Interventions
Intravenous fluid
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
Newark, Delaware • Boston, Massachusetts • Detroit, Michigan + 2 more
Conditions
Alzheimer´s Disease
Interventions
Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg, Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg, Placebo solution: Human Albumin 0.25% - 4 mL/kg, Placebo solution: Human Albumin 0.25% - 2 mL/kg
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
50 Years to 89 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 34 more
Conditions
Pancreatic Cancer
Interventions
Canakinumab, Tislelizumab, Nab-Paclitaxel, Gemcitabine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
New York, New York
Completed Phase 2 Interventional Results available

Treatment of Acute Migraine Headache in Children

NCT00355394
Conditions
Migrainous Headache
Interventions
Metoclopramide, Placebo
Drug · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
Intravenous Daclizumab, Intravenous Infliximab, Observation, Oral Rapamycin
Drug · Other
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 92 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Acute Pancreatitis
Interventions
Intravenous Fluid Therapy
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
500 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Multiple Myeloma
Interventions
BIW-8962
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Tampa, Florida • Chicago, Illinois • Detroit, Michigan + 2 more
Conditions
Cardiogenic Shock, Heart Failure, Inflammation
Interventions
Methylprednisone, Standard of Care (SOC)
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, MDS, Refractory Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
filgrastim, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Conditions
Aging
Interventions
Sham, Therapeutic Plasma Exchange, IVIG
Device · Drug
Lead sponsor
Dobri Kiprov
Industry
Eligibility
50 Years to 95 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Mill Valley, California
Conditions
Acute Lung Injury
Interventions
Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Dobutamine, Concentrate all drips and nutrition, Diuresis (furosemide) part II, Dialysis
Drug · Other · Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Clackamas, Oregon • Portland, Oregon
Conditions
COVID-19
Interventions
Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment
Biological · Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 7 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy

NCT05098067
Conditions
Hyperemesis Gravidarum, Nausea Gravidarum, Vomiting of Pregnancy
Interventions
Capsaicin Topical Cream, Metoclopramide, Ondansetron, Lactated Ringers, Intravenous
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Ischemic Stroke
Interventions
Privigen, Normal Saline
Biological · Other
Lead sponsor
Inova Health Care Services
Other
Eligibility
45 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Falls Church, Virginia
Completed Early Phase 1 Interventional Accepts healthy volunteers

Boluses of Ringer's in Surgical Kids (BRiSK Study)

NCT05285371
Conditions
Dehydration in Children, Fluid Therapy
Interventions
Urinalysis (UA), Complete Metabolic Panel (CMP), Glucose Stick Test (d-Stick), Medical Chart Review
Diagnostic Test · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 21 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Not applicable Interventional Results available

Hydrotherapy for the Reversal of Oligohydramnios

NCT01682928
Conditions
Oligohydramnios
Interventions
IV/Oral Hydration and Bedrest, Hydrotherapy
Drug · Other
Lead sponsor
Pediatrix
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Down Syndrome, Regression
Interventions
Lorazepam, Intravenous immunoglobulin (IVIG), Tofacitinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 30 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Aurora, Colorado
Conditions
Agammaglobulinemia, IgG Deficiency, Common Variable Immunodeficiency
Interventions
Immunoglobulins Intravenous (Human)
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
4 Years to 71 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
10
States / cities
Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 7 more
Conditions
Myasthenia Gravis
Interventions
Nipocalimab, Placebo, Nipocalimab SC-LIV
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
24
States / cities
Paradise Valley, Arizona • Scottsdale, Arizona • Los Angeles, California + 21 more
Conditions
Cancer,, Solid Tumors, Advanced Solid Malignancies
Interventions
AZD6918, gemcitabine, pemetrexed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Aurora, Colorado • Nashville, Tennessee
Not listed Not applicable Interventional Accepts healthy volunteers

Intravenous Fluids in Pediatric Migraine

NCT06182098
Conditions
Migraine, Migraine in Children
Interventions
1/2 maintenance fluids, Ketorolac, Diphenhydramine, Prochlorperazine, bolus
Other · Drug
Lead sponsor
Dayton Children's Hospital
Other
Eligibility
5 Years to 21 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dayton, Ohio
Conditions
AL Amyloidosis
Interventions
CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Stanford, California • Detroit, Michigan • Cleveland, Ohio
Conditions
Ovarian Torsion
Interventions
Furosemide, Normal saline
Drug
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
8 Years to 18 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hartford, Connecticut
Conditions
Neuromyelitis Optica
Interventions
Rituximab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Years to 86 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
San Francisco, California • Columbia University Medical Center 710 West 168th Street,, New York